(HealthDay)—For patients with type 2 diabetes at high cardiovascular risk, empagliflozin is associated with a reduction in incident or worsening nephropathy, according to a study published online June 14 in the New England ...
Jun 15, 2016
0
0
Empagliflozin, a recently developed diabetes drug, can effectively treat and reverse heart failure in both diabetic and non-diabetic patients, according to researchers at the Icahn School of Medicine at Mount Sinai.
Nov 13, 2020
0
14
In people with type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) is common and can progress to a severe liver disease known as nonalcoholic steatohepatitis (NASH). Now a study has found that empagliflozin, a newer ...
Mar 19, 2018
0
64
Type 2 diabetes is a chronic disease in which the body does not produce enough of the hormone insulin, which regulates blood sugar, while cells in the muscle, fat and digestive system simultaneously become less sensitive ...
Feb 23, 2023
0
46
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction. That's the finding of the EMPEROR-Reduced trial presented in a Hot ...
Aug 31, 2020
0
6
Empagliflozin reduces the risk of a composite of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction (HFpEF) with or without diabetes. That's the finding ...
Aug 27, 2021
0
176
(HealthDay)—The reduction in risk of cardiovascular (CV) death with empagliflozin is most mediated by changes in hematocrit and hemoglobin, according to research published online Dec. 4 in Diabetes Care.
Dec 26, 2017
0
6
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that the recently developed antidiabetic drug empagliflozin can treat and reverse the progression of heart failure in non-diabetic animal models. ...
Apr 18, 2019
0
9
For patients hospitalized for acute heart failure, treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin produces clinical benefit, according to a study published online April 4 in Circulation ...
Apr 13, 2022
0
9
For young people, empagliflozin is associated with improvement in glycated hemoglobin (HbA1c), according to a study published in the March issue of The Lancet Diabetes & Endocrinology.
Mar 21, 2023
0
0
